# Stephen D. Wiviott

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/stephen-d-wiviott/

## Facts

| Field | Value |
| --- | --- |
| Citations | 68,192 |
| Field | Antiplatelet Therapy and Cardiovascular Diseases |
| h-index | 84 |
| i10-index | 167 |
| Last Known Institution | Brigham and Women's Hospital |
| OpenAlex ID | https://openalex.org/A5107928205 |
| Works | 337 |

## Researcher papers

Showing 12 of 19.

- [Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes](https://scholariq.org/papers/prasugrel-versus-clopidogrel-in-patients-with-acute-coronary-syndromes/)
- [Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/dapagliflozin-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [Edoxaban versus Warfarin in Patients with Atrial Fibrillation](https://scholariq.org/papers/edoxaban-versus-warfarin-in-patients-with-atrial-fibrillation/)
- [Standardized Bleeding Definitions for Cardiovascular Clinical Trials](https://scholariq.org/papers/standardized-bleeding-definitions-for-cardiovascular-clinical-trials/)
- [Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes](https://scholariq.org/papers/ezetimibe-added-to-statin-therapy-after-acute-coronary-syndromes/)
- [Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus](https://scholariq.org/papers/saxagliptin-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials](https://scholariq.org/papers/sglt2-inhibitors-for-primary-and-secondary-prevention-of-cardiovascular-and/)
- [Cytochrome P-450 Polymorphisms and Response to Clopidogrel](https://scholariq.org/papers/cytochrome-p-450-polymorphisms-and-response-to-clopidogrel/)
- [Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents](https://scholariq.org/papers/twelve-or-30-months-of-dual-antiplatelet-therapy-after-drug-eluting-stents/)
- [Rivaroxaban in Patients with a Recent Acute Coronary Syndrome](https://scholariq.org/papers/rivaroxaban-in-patients-with-a-recent-acute-coronary-syndrome/)
- [Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes](https://scholariq.org/papers/early-intensive-vs-a-delayed-conservative-simvastatin-strategy-in-patients-with/)
- [Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial](https://scholariq.org/papers/prasugrel-compared-with-clopidogrel-in-patients-undergoing-percutaneous-coronary/)

## Researcher topics

- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)

## Researcher university

- [Brigham and Women's Hospital](https://scholariq.org/institutions/brigham-and-women-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.